Weighted Average Number of Shares Outstanding, Basic of Xilio Therapeutics, Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Xilio Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and change rate from Q3 2020 to Q3 2025.
  • Xilio Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Sep 2025 was 144M shares, a 127% increase year-over-year.
  • Xilio Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 53.5M shares, a 94.6% increase from 2023.
  • Xilio Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 27.5M shares, a 0.38% increase from 2022.
  • Xilio Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 27.4M shares, a 389% increase from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Xilio Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 144M +80.6M +127% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 96.4M +38.7M +67% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 74.7M +46.8M +168% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q4 2024 53.5M +26M +94.6% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025
Q3 2024 63.5M +35.9M +131% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 57.8M +30.3M +110% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 27.9M +479K +1.75% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q4 2023 27.5M +104K +0.38% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025
Q3 2023 27.5M +124K +0.45% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 27.5M +84.1K +0.31% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 27.4M +65.9K +0.24% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024
Q4 2022 27.4M +21.8M +389% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024
Q3 2022 27.4M +26.6M +3487% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 27.4M +26.6M +3618% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 27.4M +26.7M +3764% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023
Q4 2021 5.61M 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023
Q3 2021 764K +151K +24.7% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 736K 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 708K 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q3 2020 613K 01 Jul 2020 30 Sep 2020 10-Q 02 Dec 2021

Xilio Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 53.5M +26M +94.6% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025
2023 27.5M +104K +0.38% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025
2022 27.4M +21.8M +389% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024
2021 5.61M +5.08M +970% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023
2020 524K 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.